A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells
Name
Shaham-2010-A plasma signature o.pdf
Size
337.59 KB
Format
Adobe PDF
Checksum (MD5)
619fca12033edb9cc33357c77849918f
Author(s)
Shaham, Oded
Slate, Nancy G.
Goldberger, Olga A.
Xu, Qiuwei
Ramanathan, Arvind
Souza, Amanda
Clish, Clary
Sims, Katherine
Mootha, Vamsi K.
Date Issued
January 2010
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences
Citation
Shaham, Oded et al. “A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells.” Proceedings of the National Academy of Sciences 107.4 (2010): 1571 -1575. Copyright ©2010
Version
Final published version
Abstract
Mutations in either the mitochondrial or nuclear genomes can give rise to respiratory chain disease (RCD), a large class of devastating metabolic disorders. Their clinical management is challenging, in part because we lack facile and accurate biomarkers to aid in diagnosis and in the monitoring of disease progression. Here we introduce a sequential strategy that combines biochemical analysis of spent media from cell culture with analysis of patient plasma to identify disease biomarkers. First, we applied global metabolic profiling to spotlight 32 metabolites whose uptake or secretion kinetics were altered by chemical inhibition of the respiratory chain in cultured muscle . These metabolites span a wide range of pathways and include lactate and alanine, which are used clinically as biomarkers of RCD. We next measured the cell culture-defined metabolites in human plasma to discover that creatine is reproducibly elevated in two independent cohorts of RCD patients, exceeding lactate and alanine in magnitude of elevation and statistical significance. In cell culture extracellular creatine was inversely related to the intracellular phosphocreatine:creatine ratio suggesting that the elevation of plasma creatine in RCD patients signals a low energetic state of tissues using the phosphocreatine shuttle. Our study identifies plasma creatine as a potential biomarker of human mitochondrial dysfunction that could be clinically useful. More generally, we illustrate how spent media from cellular models of disease may provide a window into the biochemical derangements in human plasma, an approach that could, in principle, be extended to a range of complex diseases.
MIT Department
Broad Institute of MIT and Harvard
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.0906039107
